COMPANY PROFILE

Brains Bioceutical

Explore full profile

Brains Bioceutical – A Global Leader in Cannabidiol (CBD) Active Pharmaceutical Ingredient (API)

Vancouver, CanadaFounded 2010Biotech & Life Sciences

Valuation $100–250M Last recorded · 2021

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Brains Bioceutical

Brains Bioceutical operates in the rapidly growing cannabinoid market, focusing on the production of naturally sourced active pharmaceutical ingredients (APIs) for the pharmaceutical and nutraceutical industries. The company serves clients ranging from pharmaceutical companies to health and wellness brands, providing high-quality CBD ingredients that enhance their products. Brains Bioceutical leverages its partnerships with industry leaders and its unique suite of licenses to maintain a strong market position. The business model is capital-light, investing in early-stage preclinical and clinical pharmaceutical initiatives with multiple monetization opportunities. Revenue is generated through the sale of APIs and partnerships with health and wellness companies. The company is also involved in academic and clinical trials globally, supporting the development of treatments for conditions such as epilepsy, psychosis, anxiety, depression, and PTSD.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2010
Headquarters: Vancouver, Canada
Employees: 21
Open positions: None listed
Dealroom signal: 47.1/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

News

News Brains to go public via SPAC merger at $750M valuation Nov 5, 2026

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Jun 2021	$32M	$128M	DSM Venturing	↗
LATE VCOther financing	Dec 2019	$30M	$120M	Canaccord Genuity	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Brains Bioceutical website traffic

Latest recorded traffic for Brains Bioceutical is 940 monthly website visits, up 840% over the last three months. Brains Bioceutical's team grew 5% over the past year.

Latest monthly visits940 3-month web change+840% 1-year team growth+5%

Monthly website visitsJan 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
FIFibroBiologicsDeveloping therapies using fibroblasts, which are a type of cell that is found in connective tissue	Houston, United States	Operational
OBOcelot BioBiotech & Life Sciences	San Diego, United States	Operational
1T101 TherapeuticsDeveloping the first targeted glucocorticoid with all of the potency of steroids but none of the systemic toxicities	Tel Aviv-Yafo, Israel	Operational
CICianatxInnovative therapies for Diabetic Retinopathy, preventing vision loss and blindness with novel treatments	Annapolis, United States	Operational
APAculys PharmaCommitted to the patient experience including the awareness, screening, diagnosis, treatment of disease and the resolution of surrounding social issues for patients and their families confronted with neurological and psychiatric disease	Fujisawa, Japan	Acquired
BIBiofronteraSpecializing in dermatological products commercializing a portfolio of dermatological drugs specializing on the fields of photodynamic therapy (PDT) and topical antibiotics	Woburn, United States	Operational
EBEucure BiopharmaInnovative immuno-oncology targeted antibodies advancing through clinical trials	Guangzhou, China	Operational